Navigation Links
Mylan Receives Final FDA Approvals for Generic Versions of Anti-Rejection Medication CellCept(R)
Date:5/7/2009

PITTSBURGH, May 7 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. received final approvals from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Applications (ANDAs) for Mycophenolate Mofetil Tablets, 500 mg, and Mycophenolate Mofetil Capsules, 250 mg.

Mycophenolate Mofetil is the generic name for Roche's CellCept(R), which is indicated for the prevention of organ rejection in patients receiving kidney, heart or liver transplants. CellCept Tablets, 500 mg, and CellCept Capsules, 250 mg, had annual U.S. sales of approximately $680 million and $367 million, respectively, for the 12 months ending March 31, 2009, according to IMS Health. Mylan has commenced shipping both products.

Mylan Inc., which provides products to customers in more than 140 countries and territories, ranks among the leading diversified generics and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest - and highest quality - product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's third largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies. For more information, please visit http://www.mylan.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Mylan Schedules First Quarter 2009 Financial Results Conference Call and Live Webcast
2. Mylan Declares Quarterly Preferred Stock Dividend
3. Mylan Confirms First-to-File Patent Challenge Relating to Xeloda(R) Cancer Treatment
4. Andrew G. Cuneo Joins Mylan as Vice President of Global Business Development
5. Mylan Announces Clarinex(R) Settlement Agreement
6. Mylan Announces Intention to Purchase Remaining Interest in Matrix Laboratories and Delist Matrix from Indian Stock Exchanges
7. Mylans Matrix Receives Tentative FDA Approval Under PEPFAR for First Generic, Heat-Stable Version of HIV Protease Inhibitor
8. Mylans Matrix Receives WHO Approval for First Generic, Heat-Stable Version of HIV Protease Inhibitor
9. Mylan Announces Transition of Chief Financial Officer
10. Mylan Vice Chairman and CEO Robert J. Coury to Ring NASDAQ Stock Market Opening Bell
11. Mylan Schedules Fourth Quarter Financial Results Conference Call and Live Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... 2017 , ... Vighter established its NAEMT Authorized Training Center ... Trauma Life Support (PHTLS) course scholarships to four medics assigned to the Minnesota ... cooperation with the American College of Surgeons to promote critical thinking in addressing ...
(Date:3/24/2017)... ... , ... Digital Scientists, a software innovation lab specializing in web design and ... South Carolina location. The lab has set up shop at the renowned NEXT ... South Carolina clients for years from our office here in Atlanta,” explains Digital Scientists’ ...
(Date:3/24/2017)... ... , ... Texas Physical Therapy Specialists (TexPTS) is pleased to announce the ... clinic is the group’s 7th location in San Antonio and 23rd in Texas. ... care from the clinic, which opened March 22, 2017. , The team ...
(Date:3/24/2017)... ... 24, 2017 , ... Shamanic healer and teacher Anahata Ananda ... Spiritual Awakening, proudly presents her Sacred Peru retreat with world famous shaman ... journey during the Summer Solstice will also be her final international retreat, Anahata ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... they are now offering treatments for sleep apnea and TMJ at their office. ... Sleep apnea , specifically the obstructive type, is increasingly being treated at dental ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... BOTHELL, Wash. , March 23, 2017 /PRNewswire/ ... developer of advanced medical technology for non-invasive surgery, ... the Mirabilis System for treatment of uterine fibroids ... that it had received approval from the US ... study of the Mirabilis System in the United ...
(Date:3/23/2017)... -- Mosaic Life Care, based in St. Joseph, Missouri , has ... of 58 clinics, located in 22 cities, and its flagship St. Joseph Medical Center. ... the delivery of health care to its patients, including the insurance, billing and collections ... ... Mosaic Life Care St. Joseph Medical Center ...
(Date:3/23/2017)... and INDIANAPOLIS , March 23, 2017 ... ) and the William Sansum Diabetes Center have established ... people affected by diabetes through enhanced research, education and ... and cardiovascular disease bears a disproportionate weight on Latino ... said David Kerr , M.D., FRCPE, director of ...
Breaking Medicine Technology: